Hospira: In-house API production to reach 50% by 2018 through acquisitions

Hospira looking to secure in-house API production

Hospira says it intends to up in-house manufacture of its APIs from 10 to 50% by 2018 as it awaits completion of last year’s acquisition of Orchid.

Hospira has just one facility in Boulder, Colorado, that manufactures active pharmaceutical ingredients (APIs) for its Specialty Injectable Pharma (SIP) business. However, last year the firm shelled out $200m (€159m) on Aurangabad, India-based Orchid Chemicals and Pharmaceuticals in part to support its nearby finished-dose antibiotic facility in Chennai.

CEO Michael Ball said during Hospira’s Investor day last week (transcript here) he expects the Orchid transaction to be completed in the next four to six months and will help cut down the reliance on third-party API makers.

“APIs can be a very expensive part of the cost of goods equation, especially in something like oncolytics,” he told stakeholders. “Right now, Hospira only produces less than 10% of its own APIs and one of the ideas behind the Orchid acquisition is to up that percentage.”

He continued, adding by 2015: “We should be up to somewhere around 30% of our API is coming from homegrown sources, and with a couple of other inorganic moves we think we can get this number to 50% by 2018.”

Tuck-In Acquisitions

This was backed up further by CFO Thomas Werner who told stakeholders the firm is looking at further purchases in order to get vertically integrate Hospira’s API busines.

“The way we've defined it now is tuck-in acquisitions, sub $1 billion in size,” such as with orchid, he said. “We'd evaluate opportunities, but we're really looking at helping ourselves geographically expand and also getting into vertical API, but we will be opportunistic.”

Secure Supply

Matthew Stober, Senior Vice President of Operations, added such acquisitions: “Will really help drive down our cost to goods, our unit cost and help us control the overall supply chain from a quality point of view.”

Furthermore, Hospira’s investment in alternate source programs, he continued, will help “ensure that if there are interruptions of critical API supply due to regulatory or technical issues, [Hospira’ll] be able to mitigate them with these alternate sources.”

Related News

Process and procedure failings lead to FDA 483 for Hospira in India

US FDA 483 and 23 observations for Hospira's troubled Indian plant

Hospira eyes East to lower price of goods, in light of remediation

Hospira intent on growing Indian ops as EU market beckons

Good news for the Rocky Mount facility: 'Perhaps a gator in the mud, but the swamp is drained.'

Hospira confident 'swamp is drained' as US FDA ups status of Rocky Mount

Hospira: Orchid debt restructuring plan brings deal closer

Hospira edges closer to completion of Orchid API deal in India

Hospira, API, India

Hospira adds antibiotic API capacity in India

Hospira takeover of Orchid’s injectables to complete in March

Hospira buys Indian API plant from Orchid

Hospira buys Indian API plant to boost antibiotics biz

Hospira to buy injectables biz from India’s Orchid

Another 483 for Hospira

Another quarter, another 483 for Hospira, this time in Kansas

Quality remediation underway at Hospira but troubles continue

Hospira Heads in Right Direction but 483s and Warnings Still Coming

Orchid net profit tumbles as traumatic 2012 ends on a low

Orchid net profit tumbles as traumatic 2012 ends on a low